Breast Cancer

As the use of sequencing, proteomics, and immunopeptidomics increases, more targets will also be discovered, as well as more biomarkers that predict responses to treatments.

Gabriel N. Hortobagyi, MD, MACP, FASCO, a professor at the University of Texas MD Anderson Cancer Center, discussed the final data on invasive disease-free survival from the NATALEE trial of ribociclib in combination with a nonsteroid aromatase inhibitor (NSAI).

Mara Hofherr, PharmD, a clinical oncology pharmacist at Washington University, highlights key findings of the KEYNOTE-522 trial in comparison of outcomes between Black and White patients with triple-negative breast cancer.

Individuals with HR+ breast cancer could pause endocrine therapy for up to 2 years to become pregnant, without increasing the risk of recurrence.

Carly Giavatto, PharmD, discusses the CPS conducted study that highlights a first of its kind linkage to care initiative performed by health systems specialty pharmacists.

The investigational combination also delayed the median time to first chemotherapy in all age groups.

Patients with breast cancer who underwent chemotherapy and skipped RNI did not face an increased risk of disease recurrence or death 5 years post-surgery.

Trastuzumab deruxtecan and elacestrant both represent important new treatment options for subgroups of patients with breast cancer.

In the first-line setting, inavolisib plus palbociclib and fulvestrant improved PFS in patients with HR-positive breast cancers; however, further research is needed to understand the trends in OS.

Pharmacy Times will be covering the 2023 San Antonio Breast Cancer Symposium (SABCS), happening December 5 through 9 in Texas.

Further research is necessary to better understand the development and factors that contribute to CBC after PBC treatment.

In addition to predicting breast cancer outcomes, the AI tool can help determine effective treatment options in patients, sparing them from unnecessary treatments.

The investigators note that continued support during breast cancer treatment is necessary for patient comfort beyond diagnosis and the initial phases of treatment.

TcdBFBD, derived from a toxin found in Clostridium difficile, was tested in mouse models that mimicked different subtypes of breast cancer.

The study findings indicate that health care professionals significantly underreport symptoms compared to patients with breast cancer, with reported comorbidities varying.

Capivasertib is indicated for hormone receptor-positive, human epidermal growth factor 2-negative locally advanced or metastatic breast cancer with 1 or more PIK3CA/ALT1/PTEN-alterations.

Researchers determined that simultaneously targeting the BRD4 and LOXL2 proteins disrupts their interaction and inhibits the growth of triple-negative breast cancer cells.

Compared to endocrine therapy alone, the combination of ribociclib and endocrine therapy lowered the risk of cancer recurrence in patients with early breast cancer by 25.2%.

Expert panelists discuss the impact of CDK4/6 inhibitor therapy on progression-free and overall survival.

This finding underlines the need for methods that address multiple genomic alterations and targeted therapies effective in tumors driven by variations in suppressor genes or transcription factors.

Mental health treatment may be necessary when SAEs occur.

Dr Moore examines findings from the NATALEE trial.

The pharmacist’s role in addressing treatment failure for patients receiving CDK4/6 inhibitors is examined.

Rose DiMarco, PharmD, BCPS, BCOP, addresses strategies to maximize patient adherence to CDK4/6 inhibitor therapy.